Single-center utilization of donor-derived cell-free DNA testing in the management of heart transplant patients.

Keerthi T GondiAndrew KaoJodie LinardBethany A AustinMark P EverleyTimothy J FendlerTaiyeb KhumriStephanie L LawhornAnthony MagalskiMichael E NassifBrett W SperryDeepthi VodnalaA Michael Borkon

Published in: Clinical transplantation (2021)

Routine dd-cfDNA testing alongside GEP testing yielded a significant reduction in EMB volume by re-classifying GEP (+) patients into a lower risk group, without reduction in AR detection. The addition of dd-cfDNA identified patients at higher risk for AR.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
atrial fibrillation
label free